The global ocular immunosuppressants market size was exhibited at USD 4,699 million in 2024 and is projected to hit around USD 12,869 million by 2034, growing at a CAGR of 10.6% during the forecast period 2024 to 2034.
With the increasing instances of uveitis, allergic conjunctivitis, and dry eye syndrome, the demand for effective drug formulations is rising significantly that control eye inflammation without a risk of vision complications. Ocular immunosuppresents are well suited for ocular diseases as they help manage symptoms and prevent vision loss. People have become more aware of early diagnosis and treatment of ocular conditions, contributing to market expansion.
Growing geriatric population further contributes to the growth of the ocular immunosupresents market. Elderly people are more prone to ocular diseases. Age-related changes in the retina can increase the risk of damage to the blood vessels in this part of the eye, boosting the need for immunosuppressive therapies. The increasing prevalence of age-related macular degeneration and diabetic retinopathy across the globe drives the market.β―In addition, rising focus on developing targeted therapies that can elevate treatment's efficacy in uveitis and dry eye disease by reducing systemic side effects is expected to boost the market in the coming years. Also, advancements in drug development, rising healthcare spending, and increasing demand for personalized therapies are projected to boost the market growth in the coming years.
Published by Ajit Bansod
